Scholarly Index
Joel W. Neal
Stanford University; 19,124 total citations; 414 total publications; best world rank #71
Stanford University
19,124Total citations
414Total publications
54H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Lung Cancer Treatments and Mutations | Lifetime | 433 | US 214 | 99.00 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 830 | US 413 | 98.28 |
| Lung Cancer Research Studies | Lifetime | 484 | US 217 | 98.21 |
| Colorectal Cancer Treatments and Studies | Lifetime | 582 | US 246 | 98.32 |
| Lung Cancer Diagnosis and Treatment | Lifetime | 997 | US 422 | 97.62 |
| Cancer Mechanisms and Therapy | Lifetime | 840 | US 329 | 92.65 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 72 | US 32 | 99.53 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 71 | US 27 | 98.91 |
| Cancer Genomics and Diagnostics | 2021-2025 | 228 | US 108 | 98.26 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 294 | US 116 | 98.86 |
| Lung Cancer Diagnosis and Treatment | 2021-2025 | 191 | US 51 | 97.81 |
| Lung Cancer Research Studies | 2021-2025 | 227 | US 82 | 97.13 |
| Peptidase Inhibition and Analysis | 2021-2025 | 817 | US 196 | 87.53 |
| HER2/EGFR in Cancer Research | 2021-2025 | 865 | US 287 | 86.43 |
| Cancer Mechanisms and Therapy | 2021-2025 | 773 | US 98 | 74.47 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 749 | US 264 | 70.99 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 964 | US 326 | 59.52 |